Working… Menu
Trial record 10 of 1333 for:    Hematologic neoplasm

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02329847
Recruitment Status : Active, not recruiting
First Posted : January 1, 2015
Last Update Posted : May 24, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
Janssen Research & Development, LLC